E. Dobrusin

发表

Tyrosine kinase inhibitors. 15. 4-(Phenylamino)quinazoline and 4-(phenylamino)pyrido[d]pyrimidine acrylamides as irreversible inhibitors of the ATP binding site of the epidermal growth factor receptor.

W. Denny, G. Rewcastle, A. Bridges, 1999, Journal of medicinal chemistry.

2-Aminoquinazoline inhibitors of cyclin-dependent kinases.

D. W. Fry, E. Dobrusin, Y. Bathini, 2005, Bioorganic & medicinal chemistry letters.

Inhibition of binding of phospholipase C gamma 1 SH2 domains to phosphorylated epidermal growth factor receptor by phosphorylated peptides.

D. Mcnamara, E. Dobrusin, A. Saltiel, 2009, International journal of peptide and protein research.

Chapter 18. Protein Tyrosine Kinases and Cancer

D. W. Fry, E. Dobrusin, 1992 .

Cell Cycle and Biochemical Effects of PD 0183812

D. W. Fry, E. Dobrusin, W. Leopold, 2001, The Journal of Biological Chemistry.

Cell Cycle and Biochemical Effects of PD 0183812 A POTENT INHIBITOR OF THE CYCLIN D-DEPENDENT KINASES CDK4 AND CDK6*

D. W. Fry, E. Dobrusin, W. Leopold, 2001 .

Design of a potent peptide inhibitor of the epidermal growth factor receptor tyrosine kinase utilizing sequences based on the natural phosphorylation sites of phospholipase C-γ1

Juswinder Singh, D. W. Fry, A. McMichael, 1994, Peptides.

Specific, irreversible inactivation of the epidermal growth factor receptor and erbB2, by a new class of tyrosine kinase inhibitor.

W. Denny, A. Doherty, A. Bridges, 1998, Proceedings of the National Academy of Sciences of the United States of America.

Pyrido[2,3-d]pyrimidin-7-ones as specific inhibitors of cyclin-dependent kinase 4.

D. W. Fry, W. Elliott, D. Mcnamara, 2005, Journal of medicinal chemistry.

Pyrido[2,3-d]pyrimidin-7-one inhibitors of cyclin-dependent kinases.

D. Boschelli, D. W. Fry, S. Trumpp-Kallmeyer, 2000, Journal of medicinal chemistry.

Structure-activity relationships for 2-anilino-6-phenylpyrido[2,3-d]pyrimidin-7(8H)-ones as inhibitors of the cellular checkpoint kinase Wee1.

W. Denny, G. Rewcastle, A. Kraker, 2005, Bioorganic & medicinal chemistry letters.

4-Phenylpyrrolo[3,4-c]carbazole-1,3(2H,6H)-dione inhibitors of the checkpoint kinase Wee1. Structure-activity relationships for chromophore modification and phenyl ring substitution.

Daniel F Ortwine, Elizabeth A Lunney, W. Denny, 2006, Journal of medicinal chemistry.

Sequence specificity in recognition of the epidermal growth factor receptor by protein tyrosine phosphatase 1B.

D. Mcnamara, E. Dobrusin, S. Decker, 1993, The Journal of biological chemistry.

Structure-based design of a potent, selective, and irreversible inhibitor of the catalytic domain of the erbB receptor subfamily of protein tyrosine kinases.

A Whitty, A. Whitty, D. W. Fry, 1997, Journal of medicinal chemistry.

C-terminal modifications of histidyl-N-benzylglycinamides to give improved inhibition of Ras farnesyltransferase, cellular activity, and anticancer activity in mice.

A. Doherty, D. Mcnamara, E. Dobrusin, 1997, Journal of medicinal chemistry.

Differentiation of peptide molecular recognition by phospholipase Cγ‐1 Src homology‐2 domain and a mutant Tyr phosphatase PTP1bC215S

Juswinder Singh, D. Mcnamara, E. Dobrusin, 1995, Protein science : a publication of the Protein Society.

Phosphorylated fragments of the epidermal growth factor receptor: Sequence specificity for binding to phospholipase Cγ1 SH2 domains, and for kinase and phosphatase activity

J. Dixon, D. W. Fry, A. McMichael, 1994 .

2-Aminoquinazoline inhibitors of cyclin-dependent kinases.

D. W. Fry, E. Dobrusin, Y. Bathini, 2005, Bioorganic & medicinal chemistry letters.

Substrate specificity of the protein tyrosine phosphatases.

J. Dixon, D. Mcnamara, E. Dobrusin, 1993, Proceedings of the National Academy of Sciences of the United States of America.

Identification of amino acids in the N-terminal SH2 domain of phospholipase C gamma 1 important in the interaction with epidermal growth factor receptor.

D. Mcnamara, E. Dobrusin, A. Saltiel, 1994, Biochemistry.

Pyrido[2,3-d]pyrimidin-7-one Inhi-bitors of Cyclin-Dependent Kinases.

D. Boschelli, S. Trumpp-Kallmeyer, D. Mcnamara, 2001 .

Tyrosine kinase inhibitors. 1. Structure-activity relationships for inhibition of epidermal growth factor receptor tyrosine kinase activity by 2,3-dihydro-2-thioxo-1H-indole-3-alkanoic acids and 2,2'-dithiobis(1H-indole-3-alkanoic acids).

W. Denny, G. Rewcastle, D. W. Fry, 1993, Journal of Medicinal Chemistry.

Synthesis and structure-activity relationships of N-6 substituted analogues of 9-hydroxy-4-phenylpyrrolo[3,4-c]carbazole-1,3(2H,6H)-diones as inhibitors of Wee1 and Chk1 checkpoint kinases.

W. Denny, E. Lunney, E. Baker, 2008, European journal of medicinal chemistry.